Table 4.

Adverse events in colistin and ceftolozane/tazobactam treated patient groups.

Most frequent adverse events	CMS group (n = 33)	C/T group (n = 18)	p value
Clostridioides difficile colitis	3 (9.1%)	0 (0%)	0.54a
Diarrhoea	7 (21.2%)	2 (11.1%)	0.46a
Vomiting	10 (30.3%)	2 (11.1%)	0.17a
Atrial fibrillation	8 (24.2%)	3 (16.7%)	0.72a
Erythema	5 (15.2%)	1 (5.5%)	0.40a
Kidney injury	16 (48.5%)	2 (11.1%)	0.01a*
Liver function abnormalities
Increased aspartate aminotransferase	6 (18.2%)	4 (22.2%)	0.72a
Increased alanine aminotransferase	8 (24.2%)	5 (27.8%)	1.00a
Increased γ-glutamyl-transferase	11 (33.3%)	3 (16.7%)	0.32a
Increased alkaline phosphatase	8 (24.2%)	1 (5.5%)	0.13a

Data are expressed as absolute numbers (percentage).

CMS colistimethate sodium; C/T ceftolozane/tazobactam.

^aχ² test or Fisher’s exact test.

*p < 0.05.